Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia
Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia
复制标题
DOI：
10.1016/j.leukres.2011.11.002
复制
发表时间：
2012-03-01
影响因子：
2.7
通讯作者：
Renneville, Aline
中科院分区：
文献类型：
--
作者：
Abdelhamid, Emna;Preudhomme, Claude;Renneville, Aline
FLT 3内部串联重复（FLT 3-ITD）通常被认为是急性髓系白血病（AML）微小残留病（MRD）随访的不良标志物。我们的目标是在法国急性白血病协会（ALFA）治疗的20名成人AML患者中，与其他两种分子MRD标志物（NPM 1突变和WT 1过表达）进行比较，评估FLT 3-ITD作为实时定量PCR检测MRD靶点的适用性。试验。总体而言，这3种MRD标志物在17/20（85%）例病例中显示出相当的动力学。此外，我们发现诱导化疗后FLT 3-ITD MRD水平可预测完全缓解持续时间。(C)2011爱思唯尔有限公司保留所有权利。
FLT3 internal tandem duplication (FLT3-ITD) is usually considered as a bad marker for minimal residual disease (MRD) follow-up in acute myeloid leukemia (AML). Our objective was to evaluate the suitability of FLT3-ITD as a target for MRD detection by real-time quantitative PCR, in comparison with two other molecular MRD markers, NPM1 mutation and WT1 overexpression, in 20 adult AML patients treated in Acute Leukemia French Association (ALFA) trials. Overall, these 3 MRD markers showed comparable kinetics in 17/20 (85%) cases. Furthermore, we found that FLT3-ITD MRD levels after induction chemotherapy are predictive of complete remission duration. (C) 2011 Elsevier Ltd. All rights reserved.